Next Article in Journal
Evaluating Molecular Docking Software for Small Molecule Binding to G-Quadruplex DNA
Next Article in Special Issue
Improving CAR T-Cell Persistence
Previous Article in Journal
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
Previous Article in Special Issue
Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors
Review

Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy

Center for Molecular Medicine, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, 17176 Solna, Sweden
*
Author to whom correspondence should be addressed.
These authors have contributed equally.
Academic Editor: Marieke F. Fransen
Int. J. Mol. Sci. 2021, 22(19), 10800; https://doi.org/10.3390/ijms221910800
Received: 16 August 2021 / Revised: 27 September 2021 / Accepted: 28 September 2021 / Published: 6 October 2021
(This article belongs to the Special Issue Immunological Responses to Cancer Therapy)
The advent of T-cell-based immunotherapy has remarkably transformed cancer patient treatment. Despite their success, the currently approved immunotherapeutic protocols still encounter limitations, cause toxicity, and give disparate patient outcomes. Thus, a deeper understanding of the molecular mechanisms of T-cell activation and inhibition is much needed to rationally expand targets and possibilities to improve immunotherapies. Protein ubiquitination downstream of immune signaling pathways is essential to fine-tune virtually all immune responses, in particular, the positive and negative regulation of T-cell activation. Numerous studies have demonstrated that deregulation of ubiquitin-dependent pathways can significantly alter T-cell activation and enhance antitumor responses. Consequently, researchers in academia and industry are actively developing technologies to selectively exploit ubiquitin-related enzymes for cancer therapeutics. In this review, we discuss the molecular and functional roles of ubiquitination in key T-cell activation and checkpoint inhibitory pathways to highlight the vast possibilities that targeting ubiquitination offers for advancing T-cell-based immunotherapies. View Full-Text
Keywords: ubiquitination; T cells; checkpoint inhibition; cancer immunotherapy; deubiquitinases; E3 ligases ubiquitination; T cells; checkpoint inhibition; cancer immunotherapy; deubiquitinases; E3 ligases
Show Figures

Figure 1

MDPI and ACS Style

Gavali, S.; Liu, J.; Li, X.; Paolino, M. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. Int. J. Mol. Sci. 2021, 22, 10800. https://doi.org/10.3390/ijms221910800

AMA Style

Gavali S, Liu J, Li X, Paolino M. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. International Journal of Molecular Sciences. 2021; 22(19):10800. https://doi.org/10.3390/ijms221910800

Chicago/Turabian Style

Gavali, Shubhangi, Jianing Liu, Xinyi Li, and Magdalena Paolino. 2021. "Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy" International Journal of Molecular Sciences 22, no. 19: 10800. https://doi.org/10.3390/ijms221910800

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop